latest news releases from the newsroom
Cyclacel Group PLC
Cyclacel Group plc: Science Selects Cyclacel Work As Editor's Choice
DUNDEE, U.K., Nov. 8, 2004 (PRIMEZONE) -- Cyclacel Group plc ("Cyclacel"), the UK-based biopharmaceutical company, announced today that the Editor of Science magazine cited a chemistry paper by Cyclacel scientists regarding its CYC103 targeted drug discovery program. In its review of selected highlights in the recent literature, the Editor's Choice section of the 1 October 2004 issue of Science summarized a publication in which a Cyclacel team reported on its development of novel cell cycle inhibitors of the CDK2/cyclin A drug target.
TeliaSonera is to sell its stake in Infonet, USA to British Telecom
STOCKHOLM, Sweden, Nov. 08, 2004 (PRIMEZONE) -- TeliaSonera AB is to sell its stake in Infonet Services Corporation (ISC) to British Telecommunications PLC (BT). Headquartered in the USA, ISC is a global provider of voice and data communications solutions. In return for the sale of its 20% holding in ISC, TeliaSonera AB will receive approximately USD 194 million in the first halfyear 2005. TeliaSonera expects a capital gain of approximately MSEK 100.
NEW YORK, Nov. 7, 2004 (PRIMEZONE) -- Diageo (NYSE:DEO) has noted recent press coverage of the legal action, filed in New York, against it and other spirits companies by the Republic of Colombia and a number of its local government entities. The lawsuit alleges that these companies have violated the Federal RICO Act by facilitating money laundering in Colombia through their supposed involvement in the contraband trade to the detriment of government owned spirits production and distribution businesses. Although the lawsuit has not yet been served on Diageo, the Company has today taken the decision to issue this statement.
Integra LifeSciences Holdings Corp.
Integra LifeSciences Announces Third Quarter 2004 Financial Results
PLAINSBORO, N.J., Nov. 7, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its third quarter revenues and earnings. Total revenues in the third quarter of 2004 increased by $12.1 million to $59.1 million, a 26% increase over the third quarter of 2003. Product revenues increased by $15.4 million to $58.9, or 35%, over the prior year period. Excluding recently acquired product lines, third quarter 2004 product revenues increased by $9.6 million, or 22%, over the prior year period.